Department of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77551-0609, USA.
Department of Medicine, Infectious Disease Unit, Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
Curr Opin Virol. 2019 Aug;37:118-122. doi: 10.1016/j.coviro.2019.08.001. Epub 2019 Aug 31.
Lassa virus (LASV) is endemic in West Africa, causing an estimated 100000-300000 new infections and up to 5000-10000 deaths yearly. There are no vaccines and therapeutics are extremely limited. Typical case fatality rates are ∼1%, although a recent 2018 Nigerian outbreak featured an unprecedented 25.4% case fatality rate. Survivors of infection suffer a lifetime of sequelae with sudden onset sensorineural hearing loss (SNHL) being the most prevalent. The cause of this hearing loss remains unknown, and there is a critical need for further research on its mechanisms and potential therapeutics. The objective of this review is to outline the only currently available small animal model for LASV-induced hearing loss and to identify potential surrogate models.
拉萨病毒(LASV)在西非流行,每年估计有 10 万至 30 万人新感染,多达 5000 至 1 万人死亡。目前尚无疫苗,治疗方法极为有限。典型的病死率约为 1%,尽管最近 2018 年尼日利亚爆发的疫情的病死率达到了前所未有的 25.4%。感染幸存者一生都会出现后遗症,突发性感觉神经性听力损失(SNHL)是最常见的。这种听力损失的原因尚不清楚,因此迫切需要进一步研究其机制和潜在的治疗方法。本综述的目的是概述目前唯一可用的用于 LASV 诱导的听力损失的小动物模型,并确定潜在的替代模型。